insights_auto
为什么 IMM 上涨了 4.35%?
深入探索chevron_right
IMM:ASX
Immutep Ltd
AU$0.024
arrow_upward
+4.35%(+0.0010) 1 天
10月21日, GMT+11 16:10:18 · AUD
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 IMM 生成关键数据洞见…
开盘价
AU$0.02
最高价
AU$0.02
最低价
AU$0.02
市值
4068.54万
平均成交量
1483.93万
成交量
208.68万
52 周最高价
AU$0.47
52 周最低价
AU$0.02
每股收益
-AU$0.05
流通股数
14.74亿
员工人数
19
开盘价
AU$0.02
最高价
AU$0.02
最低价
AU$0.02
市值
4068.54万
平均成交量
1483.93万
成交量
208.68万
52 周最高价
AU$0.47
52 周最低价
AU$0.02
每股收益
-AU$0.05
流通股数
14.74亿
员工人数
19
新闻报道
来自网络来源和新闻合作伙伴
区块周刊BlockWeeks
·
11小时前
标普500前15大权重股占比飙至47%，互联网泡沫时期不过27%
亚洲日报
·
20小时前
纽约股市收盘：因油价下跌和企业业绩良好反弹，道琼斯指数上涨1.02%
www.tmgm.com
·
10小时前
美联储暂停降息预期与AI科技股涨势推动道指期货上涨
blockchain.news
·
13小时前
标普 500：前 15 股创纪录 46.7% 股份
资料
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis. Wikipedia
Immutep Ltd简介